论文部分内容阅读
目的:探讨早期阿托伐他汀钙片干预对2型糖尿病合并高血压患者血脂水平和炎症指标的影响。方法:选择2014年5月-2015年5月我院收治的2型糖尿病合并高血压患者130例,根据治疗方法不同,将患者分为研究组和对照组,每组各65例。对照组采取常规降压及降糖药物治疗,研究组在此基础上应用阿托伐他汀钙片。观察两组患者治疗前后血脂水平、高敏C-反应蛋白(hs-CRP)、白介素-6(IL-6)及白介素-18(IL-18)的变化情况。结果:治疗后,两组患者胆固醇(TC)及低密度脂蛋白胆固醇(LDL-C)水平均较治疗前降低,且研究组显著低于对照组,差异具有统计学意义(P<0.05);两组患者治疗前后的甘油三脂(TG)及高密度脂蛋白胆固醇(HDL-C)水平比较,差异无统计学意义(P>0.05);治疗后,两组患者hs-CRP、IL-6及IL-18水平均较治疗前降低,且研究组显著低于对照组,差异具有统计学意义(P<0.05);两组不良反应的发生率比较,差异无统计学意义(P>0.05)。结论:阿托伐他汀钙片可以有效改善2型糖尿病合并高血压患者的血脂水症,降低血清炎症因子的表达,值得临床推广应用。
Objective: To investigate the effect of early atorvastatin calcium intervention on blood lipid levels and inflammation in type 2 diabetic patients with hypertension. Methods: From May 2014 to May 2015, 130 patients with type 2 diabetes mellitus and hypertension were admitted to our hospital. According to the different treatment methods, the patients were divided into study group and control group, with 65 cases in each group. The control group to take conventional antihypertensive drugs and hypoglycemic treatment, the study group on the basis of the application of atorvastatin calcium tablets. The changes of blood lipid level, high sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6) and interleukin-18 (IL-18) in two groups before and after treatment were observed. Results: After treatment, the levels of TC and LDL-C in both groups were significantly lower than those before treatment, and the levels in the study group were significantly lower than those in the control group (P <0.05). There was no significant difference in triglyceride (TG) and high density lipoprotein cholesterol (HDL-C) between the two groups before and after treatment (P> 0.05). After treatment, hs-CRP, IL- (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05), but there was no significant difference between the two groups . Conclusion: Atorvastatin calcium tablet can effectively improve the type 2 diabetes mellitus patients with hyperlipidemia, reduce the expression of serum inflammatory cytokines, worthy of clinical application.